T he use of antithrombotic medications is a mainstay in the treatment of patients with a variety of cardiovascular and cerebrovascular disorders. Oral anticoagulation therapy dramatically reduces stroke risk in patients with atrial fibrillation (AF); aspirin and clopidogrel reduce subsequent ischemic events in patients with coronary artery disease (CAD) and ischemic stroke; and the combination of aspirin plus clopidogrel reduces ischemic outcomes in patients with acute coronary syndromes and thrombosis after stent deployment. [1] [2] [3] The most common clinical scenario for the combined use of oral anticoagulation and aspirin is that of patients with AF and CAD. In patients undergoing percutaneous coronary intervention (PCI) who have concomitant AF, triple therapy (TT) with warfarin, aspirin, and clopidogrel is being used with increasing frequency. Such combinations of antithrombotic medications are often used, but aside from selected situations such as the time-limited use of clopidogrel and aspirin after coronary artery stenting or acute coronary syndromes and the use of warfarin and aspirin in patients with mechanical heart valves, little evidence of benefit is available for these combined therapies in the majority of patients with cardiovascular disorders, and substantial evidence of risk is accumulating. 4, 5 The risk of major bleeding associated with oral anticoagulation use is quite variable but appears to be higher in clinical practice compared with clinical trials, with annual rates ranging from 3.26% to 7.20% in recent series. 5, 6 Older age and a prolonged international normalized ratio (INR) increase the risk. Current estimates suggest that Ϸ20% to 40% of patients who take oral anticoagulants are also taking an antiplatelet agent, in most cases, aspirin. 5, 6 The risk for major or life-threatening bleeding with the combined use of an oral anticoagulant plus aspirin appears to be significantly greater than the risk with the use of an anticoagulant alone. 7 Several sources of information support this conclusion (Table 1) . 8 -10 The retrospective cohort analysis of AF patients from Medicare's National Stroke Project demonstrated a major bleeding risk at 90 days of 1.3% with warfarin alone and of 1.9% with combination therapy, primarily used in patients with concomitant AF and CAD (Pϭ0.052). 8 In the SPORTIF III and V trials comparing ximelagatran with warfarin in AF patients, a retrospective analysis was performed to evaluate the bleeding risk of these therapies alone compared with the addition of up to 100 mg of daily aspirin. 9 The combination of ximelagatran plus aspirin led to an annual major bleeding rate almost identical to that of ximelagatran alone (1.9% vs 2.0%), whereas the major bleeding rate with warfarin plus aspirin was significantly greater than that with warfarin alone (3.9% vs 2.3%, Pϭ0.01). A meta-analysis of 5 randomized trials of oral anticoagulation alone versus oral anticoagulation plus aspirin (doses ranging from 50 to 1000 mg), primarily in patients with prosthetic valves, demonstrated a 2.6 relative risk for intracerebral hemorrhage with combination therapy compared with oral anticoagulation alone. 7 Two case-control studies, however, failed to find an increased risk of intracerebral hemorrhage for combination therapy. 6, 10 Recently, a large cohort study from Denmark evaluated the pattern of antithrombotic therapy use and the subsequent risk for serious bleeding, such as intracerebral hemorrhage, gastrointestinal hemorrhage, urinary tract hemorrhage, or airway hemorrhage, in AF patients after initial hospitalization for this condition during a 10-year period. 11 Of 118 606 AF patients, warfarin alone was prescribed to 50 919 patients; aspirin alone to 47 541 patients; clopidogrel alone to 3717 patients; clopidogrel and aspirin to 2859 patients; warfarin and aspirin to 18 345 patients; warfarin and clopidogrel to 1430 patients; and warfarin, aspirin, and clopidogrel to 1261 patients. The risks of fatal and nonfatal bleeding events were referenced to that of warfarin, and Cox proportional-hazards ratios were determined. The analysis was not adjusted for baseline factors predictive of potential bleeding risk. The hazard ratios (95% CIs) for aspirin and clopidogrel monotherapy were 0.93 (0.88 to 0.98) and 1.06 (0.87 to 1.29), respectively, compared with warfarin monotherapy. For aspirin plus clopidogrel, the hazard ratio was 1.66 (1.34 to 2.04) and for warfarin plus aspirin, it was 1.83 (1.72 to 1.96), indicating a substantial increase in bleeding risk compared with warfarin monotherapy. For warfarin plus clopidogrel, the hazard ratio was 3.08 (2.32 to 3.91) and for TT, it was 3.70 (2.89 to 4.76), indicating a marked increase in bleeding risk with these particular combinations. Ischemic stroke risk tended to be higher in all of the groups compared with warfarin monotherapy, aside from the warfarin plus clopidogrel group. This study provides important new evidence that the various combinations of antithrombotic drugs currently in widespread use are associated with a substantially increased risk for fatal and nonfatal bleeding compared with warfarin alone, especially so with warfarin plus clopidogrel and with TT.
The utility of warfarin in myocardial infarction (MI) patients in reducing subsequent mortality and recurrent MI has been evaluated in several trials beginning in the 1980s. Three double-blind, randomized trials of oral anticoagulation versus placebo in MI patients consistently demonstrated a significant reduction of reinfarction in the treated group and in 2 of the trials, a significant reduction in subsequent stroke as well. 12 These benefits were, however, accompanied by an increased risk for major bleeding events. Three open-label studies in MI patients (Table 2 ) demonstrated no significant difference in mortality or recurrent MI in the oral anticoagulation group compared with the aspirin group, but a significant increase in major bleeding was observed in 2 of the trials. [13] [14] [15] In 2002, the results of 2 randomized, open-label trials comparing aspirin, oral anticoagulation, and the combination were published (Table 2 ). In the WARIS II trial, 1216 acute MI patients were randomized to high-intensity oral anticoagulation (INR targetϭ2.8 to 4.2), 1206 to aspirin (160 mg), and 1208 to the combination of lower-dose aspirin (75 mg) and lower-intensity oral anticoagulation (INR targetϭ2 to 2.5). 16 A composite primary end point of death, nonfatal MI, or thromboembolic stroke occurred significantly less frequently in the 2 oral anticoagulation groups compared with the aspirin group and, importantly, the 2 oral anticoagulation groups did not differ significantly in the combined outcome. The risk of major nonfatal bleeding events was significantly increased in the oral anticoagulation monotherapy group (0.68% per year) and combination therapy group (0.57% per year) compared with the aspirin group (0.17%) but was not significantly different between the 2 oral anticoagulation groups. In the ASPECT-2 study with 3 similar treatment regimens, the same primary end point was assessed in acute MI patients, 336 treated with aspirin alone, 325 treated with anticoagulation alone, and 332 treated with combination therapy for a median follow-up time of 12 months before the study was prematurely terminated owing to enrollment difficulties. 17 Again, both oral anticoagulation groups had almost identical (5%), significantly fewer primary ischemic outcome events than did the aspirin group (9%). Major bleeding occurred in 1% of both the aspirin and oral anticoagulation monotherapy groups and in 2% of the combination therapy group. These 2 studies included patients with acute MI, and no information was provided about a history of AF; as such, they are not likely comparable regarding bleeding risk for the AF patients treated with warfarin or the combination of warfarin plus aspirin. Patients with AF and other vascular disorders such as CAD appear to be at higher risk for major bleeding events than are non-AF patients taking oral anticoagulants plus aspirin, as previously discussed, but this increased risk is likely less substantial with CAD in the absence of AF. The conclusion that can be drawn from the studies of warfarin in MI patients is that it is at least as effective as aspirin and possibly more so in reducing the risk of recurrent MI, thromboembolic stroke, and death. Warfarin is not typically used in MI patients for reducing the risk for these events because of the increased bleeding risk. These data taken together, however, suggest that it can serve as a stand-alone therapy in MI patients who also have AF requiring warfarin to reduce stroke risk. Published data to date offer no obvious rationale for adding aspirin to warfarin in CAD patients with AF unless they have a coronary stent, because the combination appears to increase bleeding risk substantially, and warfarin alone protects against the risk of both stroke and recurrent MI.
Another common clinical scenario is one in which multiple antithrombotic drugs are used in the AF patient undergoing PCI. After stent placement, there is clear evidence that combination therapy with aspirin plus clopidogrel is better than monotherapy in reducing major adverse cardiac events (cardiac death, acute MI, and revascularization). 18, 19 Dual antiplatelet therapy is rec- Fisher and Loscalzo Combination Antithrombotic Therapyommended for 30 days after bare-metal stent deployment and for at least 1 year after drug-eluting stent deployment, 20 although recent data suggest that monotherapy with aspirin beyond 12 months is as effective as dual antiplatelet therapy in reducing stent thrombosis. 21, 22 Such dual antiplatelet therapy is not as effective as warfarin for reducing stroke risk in AF patients, for which reason all 3 drugs (TT) are used in many AF patients after stent placement. 23 It should be acknowledged that dual antiplatelet therapy with aspirin and clopidogrel clearly increases the risk of moderate/major bleeding as demonstrated in the MATCH and CHARISMA trials in nonstented patients. 24, 25 This concern about bleeding risk with dual therapy is, however, outweighed by the substantial benefit of reducing stent thrombosis but should encourage clinicians to adhere to the time-limited use of dual antiplatelet therapy after stent placement. A number of case series have reported variable bleeding risk with TT, but in aggregate, they suggest that the risk is greater with TT than with dual antiplatelet therapy or warfarin alone. 26 This conclusion is amply supported by the large case-control series from Denmark described earlier. 11 Based on these and other data reviewed here, one suggested approach to managing TT in these patients is to use lower doses of aspirin combined with tight control of the INR with a target of 2.0. 27 A commonality shared by AF patients with symptomatic CAD and those with AF who undergo PCI is the lack of adequate clinical trial data to guide evidence-based decision making about the risks and benefits of the various antithrombotic regimens used in clinical practice. This lack of evidence has led to confusion about how best to maximize the reduction of ischemic events with an acceptable risk of serious bleeding side effects. Appropriate clinical trials are clearly needed, and their initiation in the near future should be encouraged. For AF plus CAD without PCI, a randomized, double-blind trial comparing warfarin alone to warfarin plus aspirin would be useful, with a combined end point that includes both major adverse cardiac events plus ischemic stroke and serious bleeding side effects. After stent placement in AF patients, a trial comparing TT, warfarin plus aspirin or clopidogrel, and clopidogrel plus aspirin should be considered. Again, a combined end point of ischemic and hemorrhagic outcomes would be most appropriate. Some clinicians may be reluctant to randomize patients to such trials; however, in our view, clinical equipoise is clearly present currently, and only such carefully designed and conducted prospective trials will provide the evidence needed for judicious therapeutic decisions in the future.
With the recent US Food and Drug Administration approval of dabigatran, a direct thrombin inhibitor, for stroke prevention in AF patients, a new era of antithrombotic therapy has dawned. In the key trial supporting the approval of dabigatran, the dose of this new drug significantly reduced the risk of ischemic stroke when compared with warfarin, with a similar risk for major bleeding. 28 Importantly, the risk of intracerebral hemorrhage was greater with warfarin than with dabigatran, but the rate of gastrointestinal hemorrhage was greater with dabigatran than with warfarin. The risk of bleeding events in this trial with the use of aspirin combined with warfarin or dabigatran was not reported in the primary publication, but the data should be forthcoming. If these data demonstrate that the combination of dabigatran plus aspirin carries no greater risk for major bleeding than dabigatran alone, then some of the current concerns about the combined use of warfarin plus aspirin in AF patients with CAD may be alleviated as dabigatran use increases. However, if the dabigatran plus aspirin combination has a significantly increased bleeding risk, then the current concerns and need for future trials that are pertinent to the warfarin plus aspirin combination will carry over. It should be acknowledged that dabigatran was associated with a modestly increased risk for MI, the implications of which for the treatment of AF in patients with CAD is as yet uncertain. The potential use of dabigatran and clopidogrel plus aspirin after PCI is entirely unexplored, regarding both bleeding risk and prevention of subsequent stent thrombosis and ischemic events.
Two factor Xa inhibitors, apixaban and rivaroxaban, have completed clinical trials in comparison with warfarin for preventing ischemic stroke in AF patients, 29 with the results of one trial recently released showing that rivaroxaban demonstrated superior efficacy over warfarin in the ontreatment analysis for reducing embolism and noninferiority on the intention-to-treat analysis with a comparable risk of major bleeding. 30 If these agents are ultimately approved for use as stroke prevention therapy in AF patients, similar concerns regarding their use with aspirin or aspirin plus clopidogrel will arise. It is very likely that clinical trials will be needed with these newer agents to assess the risks and benefits of monotherapy versus combinations with an antiplatelet agent in patients with AF plus CAD or after stenting. Their design will likely need to be similar to those proposed for warfarin and aspirin and/or clopidogrel.
Prasugrel is a third-generation thienopyridine that proved superior to clopidogrel after PCI in reducing ischemic events, cardiac death, and stent thrombosis, but its use was associated with an increased risk of major or fatal bleeding. 31, 32 Nonthienopyridine platelet inhibitors, such as ticagrelor, may also prove superior to clopidogrel but with essentially equivalent overall bleeding risk. 33 The role of these newer agents in the future and their bleeding risk when used in combination with warfarin or other newer anticoagulants remain to be determined.
The development of these novel antithrombotic drugs will likely further complicate the possible combinations of antithrombotic therapies to which patients are exposed. In addition, despite their development, it is likely that warfarin will continue to be used in a large number of AF patients worldwide for the foreseeable future. Therefore, the combined use of an anticoagulant plus aspirin and/or clopidogrel will also continue to be used, especially as the incidence of AF increases in an aging population 34 and more AF patients undergo PCI. The need for clinical trials to determine the safety and efficacy of such combinations remains paramount and is essential for informed decision making in the management of these challenging patients.
